ReviewInflammopharmacology2025
Therapeutic perspective of postbiotics in managing health of women with polycystic ovarian syndrome: a holistic approach.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities.Biomedicines · 2026Review
- The insulin resistance-systemic vascular resistance-isolated diastolic hypertension axis: a metabolic framework for an overlooked hypertension phenotype.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic Ovary Syndrome (PCOS) is an amalgamation of several factors such as complex combination of endocrine and metabolic disorder caused due to insulin resistance, hyperandrogenism and chronic inflammation. Research shows that postbiotics and their metabolic byproducts represent a new therapeutic opportunity for PCOS treatment. Postbiotics produce various therapeutic properties including anti-inflammatory, antioxidant and immunomodulatory effects that assist in balancing the metabolism. Postbiotics strengthen gut wall integrity and reduces inflammation while it affects the interaction between gut and ovaries to stabilize hormone regulation and insulin activity. Postbiotic compounds containing short-chain fatty acids (SCFAs) and microbial-derived enzymes possess the ability to enhance glucose metabolism and reduce androgen excess and support ovarian function. Malfunctioning of the gut leads to several abnormalities such as anorexia, weight gain and maintaining healthy gut homeostasis restores the same. Additionally, it restores menstrual irregularity and ovulation. Postbiotics have superior stability characteristics which provide safe operation during production and simplified formulation processes. The nature of postbiotics emerges as a promising therapy for managing PCOS since they address metabolic and reproductive disorders through microbiome-based operations.
Indexed as
Identifiers
41129014What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.